Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of bimekizumab versus placebo in active ankylosing spondylitis
NL-OMON55807Phase 3Active, not recruiting
- Sponsor
- UCB
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ankylosing spondylitis (AS) comparing Bimekizumab with Placebo to bimekizumab (2 arms). Primary endpoint: ASAS40 response at Week 16. Started Jan 2020; status: active, not recruiting.
02
Drugs
bimekizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NL-OMON55807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55807.